Toll-like receptor signaling in multiple myeloma cells promotes the expression of pro-survival genes B-cell lymphoma 2 and MYC and modulates the expression of B-cell maturation antigen.

Autor: Tryggestad SS; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Roseth IA; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Aass KR; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Ørning NEH; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Mjelle R; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Pathology, St. Olavs University Hospital, Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Standal T; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Jun 07; Vol. 15, pp. 1393906. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024).

High concentrations of soluble endoglin can inhibit BMP9 signaling in non-endothelial cells.

Autor: Andersson-Rusch C; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.; Department of Hematology, St. Olav's University Hospital, Trondheim, Norway., Liu B; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK., Quist-Løkken I; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway., Upton PD; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK., Olsen OE; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway., Yang X; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK., Tong Z; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK., Morrell NW; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK., Holien T; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway. toril.holien@ntnu.no.; Department of Hematology, St. Olav's University Hospital, Trondheim, Norway. toril.holien@ntnu.no.; Department of Biomedical Laboratory Science, NTNU, Trondheim, Norway. toril.holien@ntnu.no.; Department of Immunology and Transfusion Medicine, St. Olav's University Hospital, Trondheim, Norway. toril.holien@ntnu.no., Li W; Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, School of Clinical Medicine, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0BB, UK. wl225@cam.ac.uk.

Publikováno v: Scientific reports [Sci Rep] 2023 Apr 24; Vol. 13 (1), pp. 6639. Date of Electronic Publication: 2023 Apr 24.

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan.

Autor: Håland E; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Moen IN; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway., Veidal E; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Misund K; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Slørdahl TS; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway., Starheim KK; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway.

Publikováno v: Oncotarget [Oncotarget] 2021 Oct 12; Vol. 12 (21), pp. 2158-2168. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021).

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Autor: Giacomini, Arianna¹ (AUTHOR) arianna.giacomini@unibs.it, Taranto, Sara² (AUTHOR), Gazzaroli, Giorgia¹ (AUTHOR), Faletti, Jessica¹ (AUTHOR), Capoferri, Davide¹ (AUTHOR), Marcheselli, Raffaella² (AUTHOR), Sciumè, Margherita² (AUTHOR), Presta, Marco¹ (AUTHOR), Sacco, Antonio² (AUTHOR), Roccaro, Aldo M.² (AUTHOR) aldomaria.roccaro@asst-spedalicivili.it

Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 11/1/2024, Vol. 43 Issue 1, p1-17. 17p.

Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.

Autor: Olsen OE; Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, 7491 Trondheim, Norway.; Department of Hematology, St. Olav's University Hospital, 7030 Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, 7491 Trondheim, Norway., Elsaadi S; Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, 7491 Trondheim, Norway., Jacobi C; Novartis Institutes for BioMedical Research Basel, Musculoskeletal Disease Area, Novartis Pharma AG, CH-4056 Basel, Switzerland., Martinez-Hackert E; Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA., Holien T; Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, 7491 Trondheim, Norway.; Department of Hematology, St. Olav's University Hospital, 7030 Trondheim, Norway.

Publikováno v: Biomolecules [Biomolecules] 2020 Mar 29; Vol. 10 (4). Date of Electronic Publication: 2020 Mar 29.